Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.7M | $51.7M | $38.4M | $42.7M | $42.7M | $61.9M | $67.8M | $154M | $62.0M | $102M |
| Revenue growth | — | -13.4% | -25.7% | 11.2% | -0.0% | 44.8% | 9.5% | 126.8% | -59.6% | 65.2% |
| Operating income | $1.36M | -$19.3M | -$37.2M | -$55.5M | -$71.1M | -$98.5M | -$129M | -$89.3M | -$238M | -$158M |
| Operating margin | 2.3% | -37.2% | -96.9% | -129.8% | -166.3% | -159.2% | -190.3% | -58.1% | -384.3% | -154.5% |
| Net income | $1.70M | -$19.7M | -$35.3M | -$119M | -$32.1M | -$106M | -$119M | -$107M | -$227M | -$191M |
| Net margin | 2.8% | -38.1% | -91.9% | -278.9% | -75.2% | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (diluted) | $0.00 | -$43.95 | -$6.13 | -$2.43 | -$0.99 | -$2.29 | -$2.35 | -$1.78 | -$29.40 | -$22.49 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.2M | -$37.1M | $12.7M | -$65.0M | -$67.8M | -$81.7M | $3.55M | -$112M | -$192M | -$177M |
| Capital expenditures | $4.39M | $3.32M | $1.56M | — | — | — | — | — | — | — |
| Free cash flow | -$17.5M | -$40.4M | $11.1M | — | — | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | $7.00K | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.6M | $22.0M | $125M | $4.96M | $206M | $30.4M | $47.3M | $69.3M | $190M | $58.1M |
| Total assets | — | $40.8M | $223M | $156M | $394M | $341M | $407M | $471M | $387M | $174M |
| Total liabilities | — | $47.3M | $91.6M | $58.6M | $62.1M | $88.8M | $190M | $321M | $343M | $306M |
| Long-term debt | — | — | $10.0M | $8.88M | $24.5M | $15.7M | $3.77M | $0.00 | — | — |
| Shareholders' equity | -$90.9M | -$109M | $132M | $97.8M | $332M | $253M | $217M | $150M | $44.6M | -$132M |
| Retained earnings | — | -$115M | -$150M | -$196M | -$228M | -$333M | -$453M | -$559M | -$787M | -$978M |
| Shares (wtd avg diluted) | — | 465K | 22.8M | 23.1M | 32.6M | 46.1M | 50.7M | 60.2M | 7.74M | 8.50M |
Every figure is extracted from SUTRO BIOPHARMA, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.